The Impact of Anemia on PSA Outcome following Radiation and Androgen Suppression Therapy in Patients with High-Risk Prostate Cancer
Diana Stripp, MD
University of Pennsylvania Cancer Center
Last Modified: November 6, 2001
Presenter: A.V. DAmico
Presenter's Affiliation: Brigham and Women's Hospital, Boston, MA
Type of Session: Scientific
It is well known that in men testosterone has a permissive effect on hemeglobin (Hb)levels in the bone marrow and on erythropoetin levels in the kidney. Androgen suppression therapy (AST), frequently used in the treatment of advanced prostate cancer, is known to cause decreases in hemeglobin levels. This is concerning because there is also evidence that anemia is associated with decreased local control in cervix and head and neck cancers. In this study, the investigators examined the relationship between Hb levels and biochemical outcome after radiation therapy (RT) and AST.
Findings suggest that anemia at the start of RT may impact negatively on PSA outcome following RT and AST in high-risk prostate cancer patients.
Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.